LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 3, 2015--
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the
Company will present at the 17th Annual BIO CEO & Investor
Conference on Tuesday, February 10th at 3:00 p.m. (ET) in New
A live webcast
and replay of the presentation will be available on the "Investors"
section of the Company's website, www.syntapharma.com.
About Synta Pharmaceuticals
Synta Pharmaceuticals Corp. is an innovative, agile biopharmaceutical
company focused on research, development and commercialization of novel
oncology medicines that change cancer patients’ lives. Synta’s lead
oncology drug candidate, ganetespib, a novel heat shock protein 90
(Hsp90) inhibitor, is currently being evaluated in several clinical
trials including the pivotal GALAXY-2 Phase 3 trial in non-small cell
lung cancer. Building on its extensive expertise in the science of
Hsp90, Synta also has a novel proprietary Hsp90-Drug Conjugate (HDC)
small molecule drug development program. IND enabling studies have
commenced for the first clinical candidate from the HDC program,
STA-12-8666, and preclinical evaluation of additional HDC candidates is
ongoing. For more information, please visit www.syntapharma.com.
Source: Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp.
Andrea Rabney, 212-600-1494
Eliza Schleifstein, 917-763-8106